Compare LYEL & IMXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYEL | IMXI |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.8M | 469.3M |
| IPO Year | 2021 | 2016 |
| Metric | LYEL | IMXI |
|---|---|---|
| Price | $17.35 | $15.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $30.60 | $15.00 |
| AVG Volume (30 Days) | 51.8K | ★ 734.8K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.02 |
| Revenue | $36,000.00 | ★ $319,601,000.00 |
| Revenue This Year | N/A | $0.83 |
| Revenue Next Year | $8,712.13 | $1.49 |
| P/E Ratio | ★ N/A | $762.00 |
| Revenue Growth | N/A | ★ 16.68 |
| 52 Week Low | $0.40 | $8.58 |
| 52 Week High | $45.00 | $15.95 |
| Indicator | LYEL | IMXI |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 27.70 |
| Support Level | $17.34 | $14.87 |
| Resistance Level | $19.02 | $15.53 |
| Average True Range (ATR) | 1.22 | 0.20 |
| MACD | -0.21 | -0.06 |
| Stochastic Oscillator | 34.78 | 32.55 |
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.